| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Estradiol 17-(β-D-Glucuronide) targets the multidrug resistance protein 2 (MRP2), an ATP-binding cassette transporter localized at the hepatocyte apical membrane. MRP2 mediates ATP-dependent transport of this glucuronide conjugate into bile. It is also an endogenous metabolite of estrogen.
|
|---|---|
| ln Vitro |
In vitro, Estradiol 17-(β-D-Glucuronide) is used as a substrate to study MRP2 transporter activity. It is also used as a standard to determine the quantity of β-estradiol 17-(β-D-glucuronide) during UDP-glucuronosyltransferase assays. It is a naturally occurring conjugated estrogen.
|
| ln Vivo |
There are no therapeutic in vivo applications for Estradiol 17-(β-D-Glucuronide). It is a metabolite and research tool.
|
| Enzyme Assay |
The in vitro transporter assay for Estradiol 17-(β-D-Glucuronide) involves measuring its transport by MRP2 in membrane vesicles or cells expressing MRP2. ATP-dependent uptake of the compound is measured using radiolabeled or fluorescently labeled substrate. It is also used as a standard in UGT assays.
|
| Cell Assay |
In vitro cell-based assays for Estradiol 17-(β-D-Glucuronide) involve treating hepatocytes or MRP2-expressing cells with the compound and measuring its transport or accumulation. Its effects on bile acid transport and cholestasis can be studied in hepatocyte models.
|
| Animal Protocol |
In vivo animal studies for Estradiol 17-(β-D-Glucuronide) involve administering the compound to animals and measuring its effects on bile flow and liver function. It is used to study mechanisms of intrahepatic cholestasis.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Estradiol 17-(β-D-Glucuronide) are not detailed in the provided literature. It is a metabolite of estrogen and is excreted in bile. It is soluble in DMSO (~66.67 mg/mL).
|
| Toxicity/Toxicokinetics |
No specific toxicity data for Estradiol 17-(β-D-Glucuronide) are available in the provided literature. It is known to cause intrahepatic cholestasis. The compound is for research use only.
|
| References | |
| Additional Infomation |
Estradiol 17-(β-D-Glucuronide) is a metabolite of estrogen and a substrate for MRP2. It can cause intrahepatic cholestasis. It is for research use only. Its CAS number is 15087-02-2.
|
| Molecular Formula |
C24H32O8.NA
|
|---|---|
| Molecular Weight |
471.49588
|
| Exact Mass |
471.199
|
| CAS # |
15087-02-2
|
| Related CAS # |
Estradiol 17-(β-D-Glucuronide)
|
| PubChem CID |
169436713
|
| Appearance |
White to off-white solid powder
|
| Source |
Endogenously produced metabolite
|
| LogP |
1.525
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
33
|
| Complexity |
723
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)[O-])O)O)O)CCC5=C3C=CC(=C5)O.[Na+]
|
| InChi Key |
UQSHTUQZFYMYFO-VGYGJRAWSA-M
|
| InChi Code |
InChI=1S/C24H32O8.Na/c1-24-9-8-14-13-5-3-12(25)10-11(13)2-4-15(14)16(24)6-7-17(24)31-23-20(28)18(26)19(27)21(32-23)22(29)30;/h3,5,10,14-21,23,25-28H,2,4,6-9H2,1H3,(H,29,30);/q;+1/p-1/t14-,15-,16+,17+,18+,19+,20-,21+,23-,24+;/m1./s1
|
| Chemical Name |
sodium;(2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-[[(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]oxy]oxane-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~66.67 mg/mL (~141.70 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (10.63 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (10.63 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 5 mg/mL (10.63 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1209 mL | 10.6045 mL | 21.2089 mL | |
| 5 mM | 0.4242 mL | 2.1209 mL | 4.2418 mL | |
| 10 mM | 0.2121 mL | 1.0604 mL | 2.1209 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
